

Set Name Query

side by side

Hit Count Set Name

result set

*DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ*L8 (cd40L or cd40 adj ligand or gp39 or 5c8) same (antibod\$) and (sclerosis)21 L8*DB=USPT; PLUR=YES; OP=ADJ*L7 (cd40L or cd40 adj ligand or gp39 or 5c8) same (antibod\$) and (sclerosis)94 L7*DB=USPT,PGPB; PLUR=YES; OP=ADJ*L6 (cd40L or cd40 adj ligand or gp39 or 5c8) same (antibod\$) same (sclerosis)21 L6L5 (cd40L or cd40 adj ligand or gp39 or 5c8) same (antibod\$) and (sclerosis)263 L5L4 L1 and (131) same (idec)0 L4L3 L1 and (131)8 L3L2 L1 and (gp39 or cd40L or cd40 adj ligand)0 L2L1 anderson-darrell\$11 L1

END OF SEARCH HISTORY

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
CD40L	77
CD40LS	0
CD40	280
CD40S	0
LIGAND	24787
LIGANDS	10603
GP39	43
GP39S	0
5C8	11
5C8S	0
SCLEROSIS	10564
((CD40L OR CD40 ADJ LIGAND OR GP39 OR 5C8) SAME (ANTIBOD\$) AND (SCLEROSIS)).JPAB,EPAB,DWPI.	21

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database	▲
US Pre-Grant Publication Full-Text Database	
JPO Abstracts Database	
EPO Abstracts Database	
Derwent World Patents Index	
IBM Technical Disclosure Bulletins	▼

Search:

L8

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

DATE: Monday, June 23, 2003 [Printable Copy](#) [Create Case](#)

b 410

23jun03 12:49:26 User208760 Session D2317.1
\$0.34 0.096 DialUnits File1
\$0.34 Estimated cost File1
\$0.34 Estimated cost this search
\$0.34 Estimated total session cost 0.096 DialUnits

File 410:Chronolog(R) 1981-2003/Mar
(c) 2003 The Dialog Corporation

Set Items Description

? set hi ;set hi

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? begin 5,73,155,399

23jun03 12:49:30 User208760 Session D2317.2
\$0.00 0.071 DialUnits File410
\$0.00 Estimated cost File410.
\$0.01 TELNET
\$0.01 Estimated cost this search
\$0.35 Estimated total session cost 0.167 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2003/Jun W3

(c) 2003 BIOSIS

File 73:EMBASE 1974-2003/Jun W3

(c) 2003 Elsevier Science B.V.

*File 73: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

File 155:MEDLINE(R) 1966-2003/Jun W3

(c) format only 2003 The Dialog Corp.

*File 155: Medline has been reloaded and accession numbers have changed. Please see HELP NEWS 155.

File 399:CA SEARCH(R) 1967-2003/UD=13826

(c) 2003 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement. Alert feature enhanced for multiple files, etc. See HELP ALERT.

Set Items Description

? e au=anderson darrell ?

Ref	Items	Index-term
E1	1	AU=ANDERSON DARREL R
E2	7	AU=ANDERSON DARRELL
E3	0	*AU=ANDERSON DARRELL ?
E4	4	AU=ANDERSON DARRELL E
E5	7	AU=ANDERSON DARRELL R
E6	1	AU=ANDERSON DARWIN
E7	8	AU=ANDERSON DARWIN W
E8	1	AU=ANDERSON DARYLL
E9	5	AU=ANDERSON DAVE
E10	78	AU=ANDERSON DAVID
E11	31	AU=ANDERSON DAVID A
E12	1	AU=ANDERSON DAVID ANDREW

Enter P or PAGE for more

? s e1-e5

1	AU=ANDERSON DARREL R
7	AU=ANDERSON DARRELL
0	AU=ANDERSON DARRELL ?
4	AU=ANDERSON DARRELL E
7	AU=ANDERSON DARRELL R

S1 19 E1-E5
 ? s s1 and (gp30 or cd40L or cd40(W)ligand)
 19 S1
 305 GP30
 4488 CD40L
 17947 CD40
 347657 LIGAND
 8202 CD40(W)LIGAND
 S2 0 S1 AND (GP30 OR CD40L OR CD40(W)LIGAND)
 ? s idec(W)131
 751 IDEC
 67583 131
 S3 29 IDEC(W)131
 ? rd s3
 ...completed examining records
 S4 18 RD S3 (unique items)
 ? t s4/3/all

4/3/1 (Item 1 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2003 BIOSIS. All rts. reserv.

14198069 BIOSIS NO.: 200300192098
 Therapeutic intervention of Multiple Sclerosis with a CD40 ligand
 antagonist: A Phase I clinical Trial.
 AUTHOR: Fadul Camilo E(a); Ryan Kathleen A(a); Noelle Randolph J(a);
 Wishart Heather A(a); Saykin Andrew J(a); Mamourian Alexander C(a);
 Totoritis Mark C; Hickey William F(a); Thall Aron D; Tosteson Tor D(a);
 Kasper Lloyd H(a)
 AUTHOR ADDRESS: (a)Lebanon, NH, USA**USA
 JOURNAL: Neurology 60 (5 Supplement 1):pA84 March 11 2003 2003
 MEDIUM: print
 CONFERENCE/MEETING: 55th Annual Meeting of the American Academy of
 Neurology Honolulu, Hawaii, USA March 29-April 05, 2003
 ISSN: 0028-3878
 RECORD TYPE: Citation
 LANGUAGE: English

4/3/2 (Item 2 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2003 BIOSIS. All rts. reserv.

14169491 BIOSIS NO.: 200300163520
 Studies investigating pretransplant donor-specific blood transfusion,
 rapamycin, and the CD154-specific antibody IDEC-131 in a
 nonhuman primate model of skin allotransplantation.
 AUTHOR: Xu He; Montgomery Sean P; Preston Edwin H; Tadaki Douglas K; Hale
 Douglas A; Harlan David M; Kirk Allan D(a)
 AUTHOR ADDRESS: (a)Center Drive, Room 11S/219, Building 10, Bethesda, MD,
 20892, USA**USA E-Mail: allank@intra.niddk.nih.gov
 JOURNAL: Journal of Immunology 170 (5):p2776-2782 March 1 2003 2003
 MEDIUM: print
 ISSN: 0022-1767
 DOCUMENT TYPE: Article
 RECORD TYPE: Abstract
 LANGUAGE: English

4/3/3 (Item 3 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2003 BIOSIS. All rts. reserv.

13581031 BIOSIS NO.: 200200209852

Immuno-monitoring after a single injection of humanized monoclonal antibody to CD40 ligand in patients with chronic ITP.

AUTHOR: Kuwana Masataka(a); Nomura Shosaku; Fujimura Kingo; Nagasawa Toshiro; Muto Yoshitomo; Kurata Yoshiyuki; Tanaka Shigeru; Ikeda Yasuo(a)

AUTHOR ADDRESS: (a)Keio University, Tokyo**Japan

JOURNAL: Blood 98 (11 Part 1):p441a November 16, 2001

MEDIUM: print

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001

ISSN: 0006-4971

RECORD TYPE: Abstract

LANGUAGE: English

4/3/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13101484 BIOSIS NO.: 200100308633

A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation.

AUTHOR: Brams Peter; Black Amelia; Padlan Eduardo A; Hariharan Kandasamy; Leonard John; Chambers-Slater Karen; Noelle Randolph J; Newman Roland(a)

AUTHOR ADDRESS: (a)IDEC Pharmaceuticals Corporation, 3010 Science Park

Road, San Diego, CA, 92121: rnewman@idecpharm.com**USA

JOURNAL: International Immunopharmacology 1 (2):p277-294 February, 2001

MEDIUM: print

ISSN: 1567-5769

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

4/3/5 (Item 5 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13046214 BIOSIS NO.: 200100253363

Monotherapy with anti-CD40 ligand antibody (IDEC 131) for non-human primate allograft heart transplantation.

AUTHOR: Pfeiffer S(a); Zorn G L III(a); Azimzadeh A M(a); Atkinson J(a);

Newman R; Pierson R N III(a)

AUTHOR ADDRESS: (a)Vanderbilt University, Nashville, TN**USA

JOURNAL: Journal of Heart and Lung Transplantation 20 (2):p250 February, 2001

MEDIUM: print

CONFERENCE/MEETING: Twenty-First Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation Vancouver, Canada April 25-28, 2001

SPONSOR: International Society for Heart and Lung Transplantation

ISSN: 1053-2498

RECORD TYPE: Citation

LANGUAGE: English

SUMMARY LANGUAGE: English

4/3/6 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

12892011 BIOSIS NO.: 200100099160

Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.

AUTHOR: Davis John C Jr(a); Totoritis Mark C; Rosenberg Jay; Sklenar Thomas A; Wofsy David
AUTHOR ADDRESS: (a)Division of Rheumatology, University of California, San Francisco, 533 Parnassus Ave., San Francisco, CA, 94143**USA
JOURNAL: Journal of Rheumatology 28 (1):p95-101 January, 2001
MEDIUM: print
ISSN: 0315-162X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

4/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

12240094 BIOSIS NO.: 199900534943
Results of a Phase I, single-dose, dose-escalating trial of a humanized anti-CD40L monoclonal antibody (IDEC-131) in patients with systemic lupus erythematosus (SLE).
AUTHOR: Davis John C Jr(a); Totoritis Mark C; Sklenar Thomas A; Wofsy David
AUTHOR ADDRESS: (a)San Francisco, CA**USA
JOURNAL: Arthritis & Rheumatism 42 (9 SUPPL.):pS281 Sept., 1999
CONFERENCE/MEETING: 63rd Annual Scientific Meeting of the American College of Rheumatology and the 34th Annual Scientific Meeting of the Association of Rheumatology Health Professionals Boston, Massachusetts, USA November 13-17, 1999
ISSN: 0004-3591
RECORD TYPE: Citation
LANGUAGE: English

4/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

11995242 BIOSIS NO.: 199900275761
A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation.
AUTHOR: Chambers-Slater Karen(a); Brams Peter(a); Black Amelia(a); Padlan Eduardo A; Shestowsky William(a); Shearin Tracey(a); Nguyen Mai-Lan(a); Noelle Randolph J; Hanna Nabil(a); Newman Roland(a)
AUTHOR ADDRESS: (a)IDEC Pharmaceuticals Corporation, 11011 Torreyana Road, San Diego, CA, 92121**USA
JOURNAL: FASEB Journal 13 (5 PART 2):pA988 March 15, 1999
CONFERENCE/MEETING: Annual Meeting of the Professional Research Scientists on Experimental Biology 99 Washington, D.C., USA April 17-21, 1999
SPONSOR: Federation of American Societies for Experimental Biology
ISSN: 0892-6638
RECORD TYPE: Citation
LANGUAGE: English

4/3/9 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

12075716 EMBASE No: 2003187756
Sirolimus and islet transplants
Hering B.J.; Wijkstrom M.
Dr. B.J. Hering, Department of Surgery, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455 United States
Transplantation Proceedings (TRANSPLANT. PROC.) (United States) 2003

, 35/3 SUPPL. (187S-190S)
CODEN: TRPPA ISSN: 0041-1345
DOCUMENT TYPE: Journal ; Conference Paper
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 36

4/3/10 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

12007721 EMBASE No: 2003118213
What's in the pipeline? New immunosuppressive drugs in transplantation
Vincenti F.
F. Vincenti, Univ. of California, San Francisco, Kidney Transplant
Service, 505 Parnassus Avenue, San Francisco, CA 94143-0116 United
States
AUTHOR EMAIL: vincentif@surgery.ucsf.edu
American Journal of Transplantation (AM. J. TRANSPLANT.) (Denmark)
2002, 2/10 (898-903)
CODEN: AJTMB ISSN: 1600-6135
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 46

4/3/11 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11985759 EMBASE No: 2003096191
IDEC-131: IDEC/Eisai
Dumont F.J.
F.J. Dumont, Merck Research Laboratories, Department of Immunology, Room
RY80W107, 126 East Lincoln Avenue, Rahway, NJ 07065 United States
AUTHOR EMAIL: francis dumont@merck.com
Current Opinion in Investigational Drugs (CURR. OPIN. INVEST. DRUGS) (
United Kingdom) 01 MAY 2002, 3/5 (725-734)
CODEN: CIDRE ISSN: 1472-4472
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 65

4/3/12 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11880834 EMBASE No: 2002453109
Treatment of Systemic Lupus Erythematosus by inhibition of T cell
costimulation with anti-CD154: A randomized, double-blind,
placebo-controlled trial
Kalunian K.C.; Davis Jr. J.C.; Merrill J.T.; Totoritis M.C.; Wofsy D.
Dr. K.C. Kalunian, 200 UCLA Medical Plaza #365, Los Angeles, CA 90095
United States
AUTHOR EMAIL: kkalunian@mednet.ucla.edu
Arthritis and Rheumatism (ARTHRITIS RHEUM.) (United States) 01 DEC
2002, 46/12 (3251-3258)
CODEN: ARHEA ISSN: 0004-3591
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 26

4/3/13 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11566931 EMBASE No: 2002138516
Update: Treatment of systemic lupus erythematosus
Alarcon-Segovia D.
Dr. D. Alarcon-Segovia, Instituto NAL Nutrition, Vasco de Quiroga #15,
Mexico City 14000 Mexico
AUTHOR EMAIL: das@innsz.mx
Arthritis Care and Research (ARTHRITIS CARE RES.) (United States)
2002, 47/2 (219-222)
CODEN: ARCRE ISSN: 0893-7524
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 14

4/3/14 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11357498 EMBASE No: 2001370645
Abetimus sodium. Treatment of systemic lupus erythematosus
Sorbera L.A.; Castan(tilde)er R.M.; Revel L.
L.A. Sorbera, Prous Science, P.O. Box 540, 08080 Barcelona Spain
Drugs of the Future (DRUGS FUTURE) (Spain) 2001, 26/7 (633-638)
CODEN: DRFUD ISSN: 0377-8282
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 21

4/3/15 (Item 7 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11326733 EMBASE No: 2001338888
Alefacept. Antipsoriatic
Sorbera L.A.; Revel L.; Fernandez R.
L.A. Sorbera, Prous Science, P.O. Box 540, 08080 Barcelona Spain
Drugs of the Future (DRUGS FUTURE) (Spain) 2001, 26/6 (527-532)
CODEN: DRFUD ISSN: 0377-8282
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 32

4/3/16 (Item 8 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11286507 EMBASE No: 2001300281
Novel therapies in the treatment of systemic lupus erythematosus
Dequet C.R.; Wallace D.J.
C.R. Dequet, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los
Angeles, CA 90048 United States
AUTHOR EMAIL: dequetc@cshs.org
Current Opinion in Investigational Drugs (CURR. OPIN. INVEST. DRUGS) (
United Kingdom) 2001, 2/8 (1045-1053)
CODEN: CIDRE ISSN: 0967-8298
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 60

4/3/17 (Item 9 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11183476 EMBASE No: 2001197890
hull124. Antipsoriatic, treatment of transplant rejection
Sorbera L.A.; Leeson P.A.; Graul A.; Revel L.
L.A. Sorbera, Prous Science, P.O. Box 540, 08080 Barcelona Spain
Drugs of the Future (DRUGS FUTURE) (Spain) 2001, 26/3 (232-238)
CODEN: DRFUD ISSN: 0377-8282
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 29

4/3/18 (Item 10 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

10918105 EMBASE No: 2000412265
Novel, non-antigen-specific therapeutic approaches to
autoimmune/inflammatory diseases
Illei G.G.; Lipsky P.E.
G.G. Illei, National Institute of Arthritis, Musculoskeletal and Skin
Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda,
MD 20892 United States
AUTHOR EMAIL: illeig@mail.nih.gov
Current Opinion in Immunology (CURR. OPIN. IMMUNOL.) (United Kingdom)
2000, 12/6 (712-718)
CODEN: COPIE ISSN: 0952-7915
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 40
? s (gp39 or cd40L or cd40(w)ligand) (10n) (antibod?) and (sclerosis or ms)
574 GP39
4488 CD40L
17947 CD40
347657 LIGAND
8202 CD40(W)LIGAND
1805465 ANTIBOD?
1780 ((GP39 OR CD40L) OR CD40(W)LIGAND) (10N) ANTIBOD?
166508 SCLEROSIS
227189 MS
S5 69 (GP39 OR CD40L OR CD40(W)LIGAND) (10N) (ANTIBOD?) AND
(SCLEROSIS OR MS)

? rd s5
...examined 50 records (50)
...completed examining records
S6 50 RD S5 (unique items)
? t s6/3/all

6/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13867160 BIOSIS NO.: 200200495981
Modulation of the CD40-**CD40 ligand** interaction using human
anti-CD40 single-chain **antibody** fragments obtained from the n-CoDeR
phage display library.
AUTHOR: Ellmark Peter; Ottosson Camilla; Borrebaeck Carl A K(a); Hager
Ann-Christin Malmborg; Furebring Christina
AUTHOR ADDRESS: (a)Department of Immunotechnology, Lund University, 220 07,

PO Box 7031, Lund**Sweden E-Mail: carl.borrebaeck@immun.lth.se
JOURNAL: Immunology 106 (4):p456-463 August, 2002
MEDIUM: print
ISSN: 0019-2805
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13811973 BIOSIS NO.: 200200440794
Activity profile in multiple sclerosis: An integrative approach. A preliminary report.
AUTHOR: Zabaleta M(a); Marino R; Borges J; Camargo B; Ordaz P; De Sanctis J B; Bianco N E
AUTHOR ADDRESS: (a)AEROCAY 1216, PO Box 02-5304, Miami, FL, 33102-5304**USA
E-Mail: inmuno@cantv.net
JOURNAL: Multiple Sclerosis 8 (4):p343-349 August, 2002
MEDIUM: print
ISSN: 1352-4585
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13691717 BIOSIS NO.: 200200320538
Blockade of CD40-CD40 ligand protects renal injury in chronic proteinuric renal disease.
AUTHOR: Wang Yiping(a); Kairaitis Lukas(a); Tay Yuet-Ching(a); Wang Yang(a); Harris David C H(a)
AUTHOR ADDRESS: (a)Department of Renal Medicine, University of Sydney at Westmead Hospital, Westmead, NSW**Australia
JOURNAL: Journal of the American Society of Nephrology 12 (Program and Abstract Issue):p666A-667A September, 2001
MEDIUM: print
CONFERENCE/MEETING: ASN (American Society of Nephrology)/ISN (International Society of Nephrology) World Congress of Nephrology San Francisco, CA, USA October 10-17, 2001
ISSN: 1046-6673
RECORD TYPE: Citation
LANGUAGE: English

6/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13498531 BIOSIS NO.: 200200127352
Treatment of T cell mediated autoimmune disorders.
AUTHOR: Noelle R J; Classen E
AUTHOR ADDRESS: Cornish, N.H.**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1216 (2):p1705 Nov. 10, 1998
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Citation
LANGUAGE: English

6/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13484942 BIOSIS NO.: 200200113763
Method to treat multiple **sclerosis** with **GP39**-specific
antibodies.

AUTHOR: Noelle Randolph J; Claassen Eric(a)
AUTHOR ADDRESS: (a)Punacker**Netherlands
JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents 1253 (2):pNo Pagination Dec. 11, 2001
MEDIUM: e-file
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

6/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

12330308 BIOSIS NO.: 200000083810
IL-12 reverses the suppressive effect of the CD40 ligand blockade on
experimental autoimmune encephalomyelitis (EAE).
AUTHOR: Constantinescu Cris S; Hilliard Brendan; Wysocka Maria; Ventura
Elvira S; Bhopale Mahendra K; Trinchieri Giorgio; Rostami A M(a)
AUTHOR ADDRESS: (a)Department of Neurology, University of Pennsylvania,
Philadelphia, PA, 19104**USA
JOURNAL: Journal of the Neurological Sciences 171 (1):p60-64 Dec. 1, 1999
ISSN: 0022-510X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

6/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

11872859 BIOSIS NO.: 199900118968
Mechanisms of immunotherapeutic intervention by anti-**CD40L** (CD154)
antibody in an animal model of multiple **sclerosis**.
AUTHOR: Howard Laurence M; Miga Amy J; Vanderlugt Carol L; Dal Canto Mauro
C; Laman Jon D; Noelle Randolph Jh; Miller Stephen D
AUTHOR ADDRESS: Dep. Microbiol. Immunol., Northwestern Univ. Med. Sch.,
303 East Chicago Avenue, Chicago, IL 60611**USA
JOURNAL: Journal of Clinical Investigation 103 (2):p281-290 Jan., 1999
ISSN: 0021-9738
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

11748371 BIOSIS NO.: 199800529067
Analysis of EAE-blockade by targeting CD40-CD40L interactions in mice and
marmoset monkeys.

AUTHOR: Laman J D(a); 'T Hart B; Brok H; Van Meurs M; Schellekens M M;
Bauer J; Lassmann H; Opdenakker G; Ceuppens J; De Boer M
AUTHOR ADDRESS: (a)Erasmus Univ., Rotterdam**Netherlands
JOURNAL: Journal of Neuroimmunology 90 (1):p57 Sept. 1, 1998
CONFERENCE/MEETING: Fifth International Congress of the International
Society of Neuroimmunology Montreal, Canada August 23-27, 1998
SPONSOR: International Society of Neuroimmunology
ISSN: 0165-5728
RECORD TYPE: Citation
LANGUAGE: English

6/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

11748364 BIOSIS NO.: 199800529060
Antibody to CD40L inhibits lymph node but not spleen responses
to ongoing EAE.
AUTHOR: Howard L(a); Vanderlugt C L(a); Noelle R J; Miller S D
AUTHOR ADDRESS: (a)Northwestern Univ. Med. Sch., Evanston, IL**USA
JOURNAL: Journal of Neuroimmunology 90 (1):p56 Sept. 1, 1998
CONFERENCE/MEETING: Fifth International Congress of the International
Society of Neuroimmunology Montreal, Canada August 23-27, 1998
SPONSOR: International Society of Neuroimmunology
ISSN: 0165-5728
RECORD TYPE: Citation
LANGUAGE: English

6/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

11655505 BIOSIS NO.: 199800437236
Therapy with **antibodies** against **CD40L** (CD154) and CD44-variant
isoforms reduces experimental autoimmune encephalomyelitis induced by a
proteolipid protein peptide.
AUTHOR: Laman J D(a); Maassen C B M; Schellekens M M; Visser L; Kap M; De
Jong E; Van Puijenbroek M; Van Stipdonk M J B; Van Meurs M; Schwarzler C;
Gunthert U
AUTHOR ADDRESS: (a)Div. Immunological Infect. Dis., TNO Prevention Health,
PO Box 2215, 2301 CE Leiden**Netherlands
JOURNAL: Multiple Sclerosis 4 (3):p147-153 June, 1998
ISSN: 1352-4585
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

11577105 BIOSIS NO.: 199800357801
Reduction of atherosclerosis in mice by inhibition of CD40 signalling.
AUTHOR: Mach Francois; Schoenbeck Uwe; Sukhova Galina K; Atkinson Elizabeth
; Libby Peter(a)
AUTHOR ADDRESS: (a)Vascular Med. Atherosclerosis Unit, Cardiovascular Div.,
Dep. Med., Brigham and Women's Hosp., H**USA
JOURNAL: Nature (London) 394 (6689):p200-203 July 9, 1998
ISSN: 0028-0836
DOCUMENT TYPE: Article
RECORD TYPE: Abstract

LANGUAGE: English

6/3/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

10789000 BIOSIS NO.: 199799410145
Increased interleukin 12 production in progressive multiple **sclerosis**
: Induction by activated CD4+ T cells via CD40 ligand.
AUTHOR: Balashov Konstantin E; Smith Derek R; Khoury Samia J; Hafler David
A; Weiner Howard L(a)
AUTHOR ADDRESS: (a)Cent. Neurologic Diseases, Brigham and Women's Hosp.,
221 Longwood Ave., LMRC Room 102a, Boston,**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United
States of America 94 (2):p599-603 1997
ISSN: 0027-8424
RECORD TYPE: Abstract
LANGUAGE: English

6/3/13 (Item 13 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

10292706 BIOSIS NO.: 199698747624
CD40-CD40 ligand interactions in experimental allergic encephalomyelitis
and multiple **sclerosis**.
AUTHOR: Gerritse Koen; Laman Jon D; Noelle Randolph J; Aruffo Alejandro;
Ledbetter Jeffrey A; Boersma Wim J A; Claassen Eric(a)
AUTHOR ADDRESS: (a)Div. Immunol. Infectious Diseases, TNO Prevention
Health, POB 2215, 2301 CE, Leiden**Netherlands
JOURNAL: Proceedings of the National Academy of Sciences of the United
States of America 93 (6):p2499-2504 1996
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/14 (Item 14 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

09997749 BIOSIS NO.: 199598452667
T and B Cell Collaboration Is Essential for the Autoantibody Response to
DNA Topoisomerase I in Systemic **Sclerosis**.
AUTHOR: Kuwana Masataka; Medsger Thomas A Jr; Wright Timothy M(a)
AUTHOR ADDRESS: (a)Div. Rheumatol. Clinical Immunology, Univ. Pittsburgh
Sch. Med., E1157 Biomed. Sci. Tower, Pitts**USA
JOURNAL: Journal of Immunology 155 (5):p2703-2714 1995
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/15 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

12112012 EMBASE No: 2003223571
Gene therapy in nonhuman primate models of human autoimmune disease
t'Hart B.A.; Vervordeldonk M.; Heeney J.L.; Tak P.P.

Dr. B.A. t'Hart, Biomedical Primate Research Centre, Department of
Immunobiology, PO Box 3306, 2280 GH Rijswijk Netherlands
Gene Therapy (GENE THER.) (United Kingdom) 2003, 10/10 (890-901)
CODEN: GETHE ISSN: 0969-7128
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 94

6/3/16 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

12061685 EMBASE No: 2003172203
Disease-modifying therapies in multiple sclerosis: An update on
recent and ongoing trials and future strategies
Wiendl H.; Kieseier B.C.
Dr. H. Wiendl, Department of Neurology, University of Tübingen,
Hoppe-Seyler-Strasse 3, D-72076 Tübingen Germany
AUTHOR EMAIL: heinz.wiendl@uni-tuebingen.de
Expert Opinion on Investigational Drugs (EXPERT OPIN. INVEST. DRUGS) (
United Kingdom) 01 APR 2003, 12/4 (689-712)
CODEN: EOIDE ISSN: 1354-3784
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 180

6/3/17 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11985759 EMBASE No: 2003096191
IDEC-131: IDEC/Eisai
Dumont F.J.
F.J. Dumont, Merck Research Laboratories, Department of Immunology, Room
RY80W107, 126 East Lincoln Avenue, Rahway, NJ 07065 United States
AUTHOR EMAIL: francis.dumont@merck.com
Current Opinion in Investigational Drugs (CURR. OPIN. INVEST. DRUGS) (
United Kingdom) 01 MAY 2002, 3/5 (725-734)
CODEN: CIDRE ISSN: 1472-4472
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 65

6/3/18 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11936266 EMBASE No: 2003047712
Natural killer T cells as targets for therapeutic intervention in
autoimmune diseases
Wilson M.T.; Van Kaer L.
L. Van Kaer, Dept. of Microbiology and Immunology, Vanderbilt Univ.
School of Medicine, Rudolph Light Hall, Nashville, TN 37232-0295 United
States
AUTHOR EMAIL: luc.van.kaer@vanderbilt.edu
Current Pharmaceutical Design (CURR. PHARM. DES.) (Netherlands) 2003
, 9/3 (201-220)
CODEN: CPDEF ISSN: 1381-6128
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 169

6/3/19 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11738277 EMBASE No: 2002311053
Protection of marmoset monkeys against EAE by treatment with a murine antibody blocking CD40 (mu5D12)
Laman J.D.; 't Hart B.A.; Brok H.; van Meurs M.; Schellekens M.M.; Kasran A.; Boon L.; Bauer J.; de Boer M.; Ceuppens J.
J.D. Laman, Department of Immunology, Erasmus MC, P.O. Box 1738, 3000 DR Rotterdam Netherlands
AUTHOR EMAIL: Laman@immu.fgg.eur.nl
European Journal of Immunology (EUR. J. IMMUNOL.) (Germany) 2002, 32/8 (2218-2228)
CODEN: EJIMA ISSN: 0014-2980
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 33

6/3/20 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11714415 EMBASE No: 2002286963
Transient anti-CD154-mediated immunotherapy of ongoing relapsing experimental autoimmune encephalomyelitis induces long-term inhibition of disease relapses
Howard L.M.; Dal Canto M.C.; Miller S.D.
S.D. Miller, Dept. of Microbiology-Immunology, Interdept. Immunobiology Center, Northwestern Univ. Medical School, 303 East Chicago Avenue, Chicago, IL 60611 United States
AUTHOR EMAIL: s-d-miller@northwestern.edu
Journal of Neuroimmunology (J. NEUROIMMUNOL.) (Netherlands) 2002, 129/1-2 (58-65)
CODEN: JNRID ISSN: 0165-5728
PUBLISHER ITEM IDENTIFIER: S0165572802001753
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 27

6/3/21 (Item 7 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11464461 EMBASE No: 2002035925
Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis
Howard L.M.; Ostrovidov S.; Smith C.E.; Dal Canto M.C.; Miller S.D.
S.D. Miller, Dept. of Microbiology-Immunology, Northwestern Univ. Medical School, 303 East Chicago Avenue, Chicago, IL 60611 United States
AUTHOR EMAIL: s-d-miller@nwu.edu
Journal of Clinical Investigation (J. CLIN. INVEST.) (United States) 2002, 109/2 (233-241)
CODEN: JCINA ISSN: 0021-9738
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 48

6/3/22 (Item 8 from file: 73)

DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

10632320 EMBASE No: 2000097753

An alternative pathway of nitric oxide production by rat astrocytes requires specific antigen and T cell contact

Xiao B.-G.; Xu L.-Y.; Yang J.-S.; Huang Y.-M.; Link H.

B.-G. Xiao, Division of Neurology, Huddinge University Hospital, Karolinska Institute, S-141 86 Huddinge, Stockholm Sweden

Neuroscience Letters (NEUROSCI. LETT.) (Ireland) 31 MAR 2000, 283/1 (53-56)

CODEN: NELED ISSN: 0304-3940

PUBLISHER ITEM IDENTIFIER: S0304394000009149

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 19

6/3/23 (Item 9 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

07384733 EMBASE No: 1998301549

Therapy with **antibodies** against **CD40L** (CD154) and CD44-variant isoforms reduces experimental autoimmune encephalomyelitis induced by a proteolipid protein peptide

Laman J.D.; Maassen C.B.M.; Schellekens M.M.; Visser L.; Kap M.; De Jong E.; Van Puijenbroek M.; Van Stipdonk M.J.B.; Van Meurs M.; Schwarzler C.; Gunthert U.

J.D. Laman, Div. Immunological Infectious Dis., TNO Prevention and Health, PO Box 2215, 2301 CE Leiden Netherlands

Multiple Sclerosis (MULT. SCLER.) (United Kingdom) 1998, 4/3 (147-153)

CODEN: MUSCF ISSN: 1352-4585

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 25

6/3/24 (Item 10 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

07207338 EMBASE No: 1998085696

Anti-**CD40 ligand antibody** treatment of SNF1 mice with established nephritis: Preservation of kidney function

Kalled S.L.; Cutler A.H.; Datta S.K.; Thomas D.W.

Dr. S.L. Kalled, Department of Immunology, Biogen Inc., 14 Cambridge Center, Cambridge, MA 02142 United States

Journal of Immunology (J. IMMUNOL.) (United States) 01 MAR 1998, 160/5 (2158-2165)

CODEN: JOIMA ISSN: 0022-1767

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 49

6/3/25 (Item 11 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

06755494 EMBASE No: 1997036980

Increased interleukin 12 production in progressive multiple **sclerosis**: Induction by activated CD4sup + T cells via CD40 ligand

Balashov K.E.; Smith D.R.; Khoury S.J.; Hafler D.A.; Weiner H.L.

H.L. Weiner, Center for Neurologic Diseases, Brigham and Women's
Hospital, 221 Longwood Avenue, Boston, MA 02115 United States
AUTHOR EMAIL: weiner@cnd.bwh.harvard.edu
Proceedings of the National Academy of Sciences of the United States of
America (PROC. NATL. ACAD. SCI. U. S. A.) (United States) 1997, 94/2
(599-603)
CODEN: PNASA ISSN: 0027-8424
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 33

6/3/26 (Item 1 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

11280001 98158518 PMID: 9498753
Anti-CD40 ligand antibody treatment of SNF1 mice with
established nephritis: preservation of kidney function.
Kalled S L; Cutler A H; Datta S K; Thomas D W
Department of Immunology, Biogen Inc., Cambridge, MA 02142, USA.
Journal of immunology (Baltimore, Md. - 1950) (UNITED STATES) Mar 1
1998, 160 (5) p2158-65, ISSN 0022-1767 Journal Code: 2985117R
Contract/Grant No.: AR39157; AR; NIAMS; RO1-AI41985; AI; NIAID
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

6/3/27 (Item 2 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

10445889 96252591 PMID: 8690776
Therapeutic potential for blockade of the CD40 ligand, gp39.
Buhlmann J E; Noelle R J
Department of Microbiology, Dartmouth Medical School, Lebanon, New
Hampshire 03756, USA.
Journal of clinical immunology (UNITED STATES) Mar 1996, 16 (2)
p83-9, ISSN 0271-9142 Journal Code: 8102137
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

6/3/28 (Item 3 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

09343680 21103167 PMID: 11160195
Autoimmune intervention by CD154 blockade prevents T cell retention and
effector function in the target organ.
Howard L M; Miller S D
Department of Microbiology-Immunology and Interdepartmental Immunobiology
Center, Northwestern University Medical School, Chicago, IL 60611.
Journal of immunology (Baltimore, Md. - 1950) (United States) Feb 1
2001, 166 (3) p1547-53, ISSN 0022-1767 Journal Code: 2985117R
Contract/Grant No.: NS26543; NS; NINDS; NS30871; NS; NINDS; NS34819; NS;
NINDS
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM

Record type: Completed

6/3/29 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

09227485 20538473 PMID: 10978311
CD45 inhibits CD40L-induced microglial activation via negative regulation
of the Src/p44/42 MAPK pathway.
Tan J; Town T; Mullan M
Roskamp Institute, Department of Psychiatry, University of South Florida,
Tampa, Florida 33613, USA. jtan@com1.med.usf.edu
Journal of biological chemistry (UNITED STATES) Nov 24 2000, 275 (47)
p37224-31, ISSN 0021-9258 Journal Code: 2985121R
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

6/3/30 (Item 5 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

09098047 20395870 PMID: 10936029
Increased expression of CD40 ligand in activated CD4+ T lymphocytes of
systemic sclerosis patients.
Valentini G; Romano M F; Naclerio C; Bisogni R; Lamberti A; Turco M C;
Venuta S
Rheumatology Unit, II University, Naples, Italy. reumasun@mbx.netlab.it
Journal of autoimmunity (ENGLAND) Aug 2000, 15 (1) p61-6, ISSN
0896-8411 Journal Code: 8812164
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

6/3/31 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

138367591 CA: 138(24)367591k PATENT
Anti-TRAIL receptor antibodies and other therapeutic agents for treating
neoplastic, inflammatory and autoimmune diseases
INVENTOR(AUTHOR): Zhou, Tong; Ichikawa, Kimihisa; Kimberly, Robert P.;
Koopman, William J.; Oshumi, Jun; Lobuglio, Albert F.; Buchsbaum, Donald J.
LOCATION: USA
ASSIGNEE: UAB Research Foundation
PATENT: PCT International ; WO 200338043 A2 DATE: 20030508
APPLICATION: WO 2002US34420 (20021025) *US PV346402 (20011101) *US
PV391478 (20020624)
PAGES: 274 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS
; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE;
ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; SK; TR; BF; BJ; CF; CG; CI;
CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/32 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

138088661 CA: 138(7)88661t PATENT
Non-agonistic humanized antibodies to CD40 ligand
INVENTOR(AUTHOR): Darrell, Anderson; Pan, Li-zhen; Hanna, Nabil;
Rastetter, William H.; Kloetzer, William S.
LOCATION: USA
PATENT: U.S. Pat. Appl. Publ. ; US 20030012781 A1 DATE: 20030116
APPLICATION: US 874141 (20010606) *US 554840 (19951107) *US PV209584
(20000606)
PAGES: 45 pp., Cont.-in-part of U. S. Ser. No. 554,840. CODEN: USXXCO
LANGUAGE: English CLASS: 424131100; A61K-048/00A; A61K-039/395B

6/3/33 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

138088660 CA: 138(7)88660s PATENT
Monoclonal anti-CD3 antibodies for producing human CD4+ Th2 cells to treat
graft versus host disease, tumors, and autoimmune disorders
INVENTOR(AUTHOR): Fowler, Daniel H.; Hou, Jeanne; Jung, Unsu; Gress,
Ronald E.; Bishop, Michael; Levine, Bruce; June, Carl
LOCATION: USA
ASSIGNEE: United States of America, Health and Human Services; The
Trustees of the University of Pennsylvania
PATENT: PCT International ; WO 200304625 A1 DATE: 20030116
APPLICATION: WO 2002US20415 (20020626) *US PV302936 (20010702).
PAGES: 70 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-005/00A;
C12N-005/02B; A61K-039/395B; C07K-016/00B DESIGNATED COUNTRIES: AE; AG; AL
; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE;
DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP;
KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX;
MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR;
TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ;
TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW
; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE;
TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/34 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

137200261 CA: 137(14)200261v PATENT
Humanized anti-human gp39 antibodies for treating autoimmune diseases
INVENTOR(AUTHOR): Black, Amelia; Hanna, Nabil; Padlan, Eduardo A.;
Newman, Roland A.
LOCATION: USA
ASSIGNEE: Idec Pharmaceuticals Corporation
PATENT: United States ; US 6440418 B1 DATE: 20020827
APPLICATION: US 925339 (19970908) *US 554840 (19951107)
PAGES: 50 pp., Cont.-in-part of U. S. 6,001,358. CODEN: USXXAM
LANGUAGE: English CLASS: 424154100; A61K-039/395A; C07K-016/28B

6/3/35 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

137031803 CA: 137(3)31803r JOURNAL

Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys
AUTHOR(S): Boon, Louis; Laman, Jon D.; Ortiz-Buijsse, Antonio; den
Hartog, Marcel T.; Hoffenberg, Simon; Liu, Patrick; Shiau, Fred; de Boer,
Mark

LOCATION: Tanox Pharma B.V., 1069 NJ, Amsterdam, Neth.

JOURNAL: Toxicology (Toxicology) DATE: 2002 VOLUME: 174 NUMBER: 1

PAGES: 53-65 CODEN: TXCYAC ISSN: 0300-483X PUBLISHER ITEM IDENTIFIER:
0300-483X(02)00057-4 LANGUAGE: English PUBLISHER: Elsevier Science Ltd.

6/3/36 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

136117383 CA: 136(8)117383v PATENT

CD28-specific antibody compositions for use in methods of
immunosuppression

INVENTOR(AUTHOR): Yu, Xue-Zhong; Anasetti, Claudio

LOCATION: USA

PATENT: U.S. Pat. Appl. Publ. ; US 20020006403 A1 DATE: 20020117

APPLICATION: US 738546 (20001214) *US PV170857 (19991214)

PAGES: 37 pp. CODEN: USXXCO LANGUAGE: English CLASS: 424142100;
A61K-039/395A; A61K-038/13B; A61K-031/675B; A61K-031/573B

6/3/37 (Item 7 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

136036363 CA: 136(3)36363m PATENT

Non-agonistic antibodies to human gp39, compositions containing, and
therapeutic use thereof

INVENTOR(AUTHOR): Anderson, Darrell R.; Pan, Li Zhen; Hanna, Nabil;
Rastetter, William H.; Kloetzer, William S.

LOCATION: USA

ASSIGNEE: Idec Pharmaceuticals Corporation

PATENT: PCT International ; WO 200194586 A2 DATE: 20011213

APPLICATION: WO 2001US18098 (20010606) *US PV209584 (20000606)

PAGES: 130 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/13A;
C07K-016/28B; A61K-039/395B; A61P-037/06B; A61K-048/00B; C12N-015/63B;
C12N-015/86B; C12N-015/861B; C12N-015/867B; C12N-015/11B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI;
SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ;
MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ
; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL;
PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/38 (Item 8 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

135356771 CA: 135(25)356771f PATENT

Preparation and modulatory activity of human anti-CD40 antibodies

INVENTOR(AUTHOR): Mikayama, Toshifumi; Takahashi, Nobuaki; Chen, Xingjie;
Schoenberger, Stephen P.

LOCATION: USA

ASSIGNEE: Gemini Science, Inc.

PATENT: PCT International ; WO 200183755 A2 DATE: 20011108

APPLICATION: WO 2001US13672 (20010427) *US PV200601 (20000428)

PAGES: 60 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/13A;

C07K-016/28B; C12N-005/20B; C12N-005/10B; A61K-039/395B; A61P-035/00B;
A61P-037/06B; A61P-031/00B; G01N-033/68B; G01N-033/577B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;
MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;
TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD;
RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG;
ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT;
SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/39 (Item 9 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

134365711 CA: 134(26)365711t PATENT

Compositions and methods for treating autoimmune diseases and transplant
rejections

INVENTOR(AUTHOR): Chu, Keting; Wang, Changyu

LOCATION: USA

ASSIGNEE: Chiron Corporation

PATENT: PCT International ; WO 200134649 A2 DATE: 20010517

APPLICATION: WO 2000US30739 (20001108) *US PV164503 (19991109)

PAGES: 49 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-016/00A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;
MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;
TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU;
TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW;
AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE;
TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/40 (Item 10 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

134339548 CA: 134(24)339548a PATENT

Molecules targeting CD40 which do not activate CD40-expressing cells for
treatment of diseases

INVENTOR(AUTHOR): Chang, Nancy

LOCATION: USA

ASSIGNEE: Tanox, Inc.

PATENT: PCT International ; WO 200130974 A2 DATE: 20010503

APPLICATION: WO 2000US41532 (20001025) *US PV161281 (19991025)

PAGES: 19 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A

DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CN; CU;
CZ; GE; GH; GM; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; RO; RU; SD; SE; SG; SI; SK;
SL; TJ; TM; TR; TT; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU;
TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW;
AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE;
BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/41 (Item 11 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

134294513 CA: 134(21)294513s PATENT

Process for inducing functional tolerance to gene transfer products

INVENTOR(AUTHOR): Andersson, Goran K.

LOCATION: USA
ASSIGNEE: Biotransplant Incorporated
PATENT: PCT International ; WO 200125398 A2 DATE: 20010412
APPLICATION: WO 2000US26946 (20000929) *US PV157233 (19991001)
PAGES: 69 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-000/A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;
MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;
TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU;
TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW;
; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE;
BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/42 (Item 12 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

133088219 CA: 133(7)88219b PATENT
Use of CD40 engagement to alter T cell receptor usage
INVENTOR(AUTHOR): Newell, Martha K.; Wagner, David; Newell, Evan
LOCATION: USA
ASSIGNEE: University of Vermont and State Agricultural College
PATENT: PCT International ; WO 200039283 A1 DATE: 20000706
APPLICATION: WO 99US30930 (19991222) *US PV114106 (19981229)
PAGES: 50 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-005/02A;
C12N-005/06B; C12N-005/08B DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ;
BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;
TJ; TM; TR; TT; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ;
TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT; BE;
; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ;
CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/43 (Item 13 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

131031035 CA: 131(3)31035t PATENT
Use of a soluble recombinant human CD40L protein for inhibiting in vivo
immune response
INVENTOR(AUTHOR): Lazarus, Alan H.; Crow, Andrew R.; Freedman, John
LOCATION: Can.,
ASSIGNEE: Canadian Blood Services
PATENT: PCT International ; WO 9927948 A2 DATE: 19990610
APPLICATION: WO 98CA1105 (19981127) *CA 2223225 (19971128)
PAGES: 42 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/17A;
G01N-033/48B; A01K-067/027B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA;
BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; HR;
HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG;
MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR;
TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY;
DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI;
CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/44 (Item 14 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

130236467 CA: 130(18)236467m PATENT
Therapeutic use of compositions containing humanized antibodies to human gp39

INVENTOR(AUTHOR): Black, Amelia; Hanna, Nabil; Padlan, Eduardo A.; Newman, Roland A.

LOCATION: USA

ASSIGNEE: IDEC Pharmaceuticals Corporation

PATENT: PCT International ; WO 9912566 A1 DATE: 19990318

APPLICATION: WO 98US18163 (19980908) *US 925339 (19970908)

PAGES: 122 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A; C07H-021/04B; C07K-016/00B; C07K-016/18B; C07K-016/28B; C12N-005/10B; C12N-015/13B; C12P-021/08B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; HR; HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

6/3/45 (Item 15 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

130100646 CA: 130(8)100646m PATENT

Anti-CD40L immunotoxins for the treatment of diseases

INVENTOR(AUTHOR): De Boer, Mark; Den Hartog, Marcel Theodorus

LOCATION: Neth.

ASSIGNEE: Pangenetics B.V.

PATENT: PCT International ; WO 9858678 A1 DATE: 19981230

APPLICATION: WO 98NL357 (19980622) *EP 97201895 (19970620)

PAGES: 31 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-047/48A

DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

6/3/46 (Item 16 from file: 399)

DIALOG(R) File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

130094477 CA: 130(8)94477p PATENT

CD154 blockade therapy for autoimmune diseases

INVENTOR(AUTHOR): Thomas, David W.

LOCATION: USA

ASSIGNEE: Biogen, Inc.

PATENT: PCT International ; WO 9900143 A1 DATE: 19990107

APPLICATION: WO 98US13284 (19980626) *US 51072 (19970627) *US 51481 (19970701) *US 51483 (19970701) *US 51484 (19970701)

PAGES: 33 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A

DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; US; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

6/3/47 (Item 17 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

129229685 CA: 129(18)229685g PATENT
Methods of therapeutic administration of anti-CD40L monoclonal antibody
INVENTOR(AUTHOR): Kalled, Susan L.; Thomas, David W.
LOCATION: USA
ASSIGNEE: Biogen, Inc.
PATENT: PCT International ; WO 9839026 A2 DATE: 19980911
APPLICATION: WO 97US24133 (19971231) *US 40154 (19970307)
PAGES: 31 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/00A
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;
CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG;
KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL;
PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS
; MW; SD; SZ; UG; ZW; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;
MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

6/3/48 (Item 18 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

129104214 CA: 129(9)104214w PATENT
Methods of therapeutic administration of anti-CD40L compounds for
treating antibody-related disease
INVENTOR(AUTHOR): Kalled, Susan L.; Thomas, David W.
LOCATION: USA
ASSIGNEE: Biogen, Inc.; Kalled, Susan L.; Thomas, David W.
PATENT: PCT International ; WO 9830241 A1 DATE: 19980716
APPLICATION: WO 98US573 (19980109) *US 34672 (19970110) *US 40154
(19970307)
PAGES: 36 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;
CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG;
KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL;
PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU;
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS
; MW; SD; SZ; UG; ZW; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;
MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

6/3/49 (Item 19 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

126130597 CA: 126(10)130597f PATENT
Treatment of T-cell mediated autoimmune disorders with antagonists of
T-cell receptors mediating contact-dependent helper functions, and
anti-gp39 antibody
INVENTOR(AUTHOR): Noelle, Randolph J.; Claassen, Eric
LOCATION: USA
ASSIGNEE: Trustees of Dartmouth College; Nederlandse Organisatie Voor
Toegepast-Natuurwetenschappelijk Onderzoek TNO
PATENT: PCT International ; WO 9640246 A1 DATE: 19961219
APPLICATION: WO 96US9137 (19960606) *US 481735 (19950607)
PAGES: 22 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BB; BG; BR; BY; CA; CH; CN; CZ;
DE; DK; EE; ES; FI; GB; GE; HU; IL; IS; JP; KE; KG; KP; KR; KZ; LK; LR; LS;
LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG
DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FI;

FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN

6/3/50 (Item 20 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

126017804 CA: 126(2)17804h PATENT

Human antibodies derived from immunized xenomice

INVENTOR(AUTHOR): Kucherlapati, Raju; Jakobovits, Aya; Klapholz, Sue;
Brenner, Daniel G.; Capon, Daniel J.

LOCATION: USA

ASSIGNEE: Cell Genesys, Inc.

PATENT: PCT International ; WO 9634096 A1 DATE: 19961031

APPLICATION: WO 95US5500 (19950428)

PAGES: 64 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/00A

DESIGNATED COUNTRIES: AU; CA; FI; HU; JP; KR; NO; NZ

DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC;
NL; PT; SE

?

STIC-ILL

From: Gambel, Phillip
Sent: Monday, June 23, 2003 1:52 PM
To: STIC-ILL
Subject: anderson 09/874,141 amd

NPL

stic

please provide the following references to

phillip gambel
art unit 1644
308-3997

1644 mailbox 9e12

thanx

4/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

14198069 BIOSIS NO.: 200300192098

Therapeutic intervention of Multiple Sclerosis with a CD40 ligand
antagonist: A Phase I clinical Trial.

AUTHOR: Fadul Camilo E(a); Ryan Kathleen A(a); Noelle Randolph J(a);
Wishart Heather A(a); Saykin Andrew J(a); Mamourian Alexander C(a);
Totoritis Mark C; Hickey William F(a); Thall Aron D; Tosteson Tor D(a);
Kasper Lloyd H(a)

AUTHOR ADDRESS: (a)Lebanon, NH, USA**USA

JOURNAL: Neurology 60 (5 Supplement 1):pA84 March 11 2003 2003

MEDIUM: print

CONFERENCE/MEETING: 55th Annual Meeting of the American Academy of
Neurology Honolulu, Hawaii, USA March 29-April 05, 2003

ISSN: 0028-3878

RECORD TYPE: Citation

LANGUAGE: English

4/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

14169491 BIOSIS NO.: 200300163520

Studies investigating pretransplant donor-specific blood transfusion,
rapamycin, and the CD154-specific antibody IDEC-131 in a
nonhuman primate model of skin allotransplantation.

AUTHOR: Xu He; Montgomery Sean P; Preston Edwin H; Tadaki Douglas K; Hale
Douglas A; Harlan David M; Kirk Allan D(a)

AUTHOR ADDRESS: (a)Center Drive, Room 11S/219, Building 10, Bethesda, MD,
20892, USA**USA E-Mail: allank@intra.niddk.nih.gov

JOURNAL: Journal of Immunology 170 (5):p2776-2782 March 1 2003 2003

MEDIUM: print

ISSN: 0022-1767

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

4/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

AC 321 . A47

13581031 BIOSIS NO.: 200200209852

Immuno-monitoring after a single injection of humanized monoclonal antibody to CD40 ligand in patients with chronic ITP.

AUTHOR: Kuwana Masataka(a); Nomura Shosaku; Fujimura Kingo; Nagasawa Toshiro; Muto Yoshitomo; Kurata Yoshiyuki; Tanaka Shigeru; Ikeda Yasuo(a)

AUTHOR ADDRESS: (a)Keio University, Tokyo**Japan

JOURNAL: Blood 98 (11 Part 1):p441a November 16, 2001

MEDIUM: print

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001

ISSN: 0006-4971

RECORD TYPE: Abstract

LANGUAGE: English

4/3/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13101484 BIOSIS NO.: 200100308633

A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation.

AUTHOR: Brams Peter; Black Amelia; Padlan Eduardo A; Hariharan Kandasamy; Leonard John; Chambers-Slater Karen; Noelle Randolph J; Newman Roland(a)

AUTHOR ADDRESS: (a)IDEC Pharmaceuticals Corporation, 3010 Science Park Road, San Diego, CA, 92121: rnewman@idecpharm.com**USA

JOURNAL: International Immunopharmacology 1 (2):p277-294 February, 2001

MEDIUM: print

ISSN: 1567-5769

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

4/3/5 (Item 5 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13046214 BIOSIS NO.: 200100253363

Monotherapy with anti-CD40 ligand antibody (IDEC 131) for non-human primate allograft heart transplantation.

AUTHOR: Pfeiffer S(a); Zorn G L III(a); Azimzadeh A M(a); Atkinson J(a); Newman R; Pierson R N III(a)

AUTHOR ADDRESS: (a)Vanderbilt University, Nashville, TN**USA

JOURNAL: Journal of Heart and Lung Transplantation 20 (2):p250 February, 2001

MEDIUM: print

CONFERENCE/MEETING: Twenty-First Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation Vancouver, Canada April 25-28, 2001

SPONSOR: International Society for Heart and Lung Transplantation

ISSN: 1053-2498

RECORD TYPE: Citation

LANGUAGE: English

SUMMARY LANGUAGE: English

4/3/6 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

12892011 BIOSIS NO.: 200100099160

Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.

AUTHOR: Davis John C Jr(a); Totoritis Mark C; Rosenberg Jay; Sklenar Thomas A; Wofsy David

AUTHOR ADDRESS: (a)Division of Rheumatology, University of California, San Francisco, 533 Parnassus Ave., San Francisco, CA, 94143**USA

A B 145 .A2 B56

Phillip Hamel
1644 6/23
09874141

109 37868

13581071 BIOSIS NO.: 200200209852

Immuno-monitoring after a single injection of humanized monoclonal antibody to CD40 ligand in patients with chronic ITP.

AUTHOR: Kuwana Masataka(a); Nomura Shosaku; Fujimura Kingo; Nagasawa Yoshio; Muto Yoshitomo; Kurata Yoshiyuki; Tanaka Shigeru; Ikeda Yasuo(a)

AUTHOR ADDRESS: (a)Keio University, Tokyo**Japan

JOURNAL: Blood 98 (11 Part 1):p441a November 16, 2001

MEDIUM: print

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001

ISSN: 0006-4971

RECORD TYPE: Abstract

LANGUAGE: English

Vol. NO

451843

Phillip Hambl
1644 6/23
098.74141

4/3/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13101484 BIOSIS NO.: 200100308633

A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation.

AUTHOR: Brams Peter; Black Amelia; Padlan Eduardo A; Hariharan Kandasamy; Leonard John; Chambers-Slater Karen; Noelle Randolph J; Newman Roland(a)

AUTHOR ADDRESS: (a)IDEC Pharmaceuticals Corporation, 3010 Science Park Road, San Diego, CA, 92121: newman@idecpharm.com**USA

JOURNAL: International Immunopharmacology 1 (2):p277-294 February, 2001

MEDIUM: print

ISSN: 1567-5769

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

4/3/5 (Item 5 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13046214 BIOSIS NO.: 200100253363

Monotherapy with anti-CD40 ligand antibody (IDEC 131) for non-human primate allograft heart transplantation.

AUTHOR: Pfeiffer S(a); Zorn G L III(a); Azimzadeh A M(a); Atkinson J(a); Newman R; Pierson R N III(a)

AUTHOR ADDRESS: (a)Vanderbilt University, Nashville, TN**USA

JOURNAL: Journal of Heart and Lung Transplantation 20 (2):p250 February, 2001

MEDIUM: print

CONFERENCE/MEETING: Twenty-First Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation Vancouver, Canada April 25-28, 2001

SPONSOR: International Society for Heart and Lung Transplantation

ISSN: 1053-2498

RECORD TYPE: Citation

LANGUAGE: English

SUMMARY LANGUAGE: English

4/3/6 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

12892011 BIOSIS NO.: 200100099160

Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.

AUTHOR: Davis John C Jr(a); Totoritis Mark C; Rosenberg Jay; Sklenar Thomas A; Wofsy David

AUTHOR ADDRESS: (a)Division of Rheumatology, University of California, San Francisco, 533 Parnassus Ave., San Francisco, CA, 94143**USA

JOURNAL: Journal of Rheumatology 28 (1):p95-101 January, 2001
MEDIUM: print
ISSN: 0315-162X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

NPL

RC927 .A1 A7

4/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

12240094 BIOSIS NO.: 199900534943
Results of a Phase I, single-dose, dose-escalating trial of a humanized anti-CD40L monoclonal antibody (IDEC-131) in patients with systemic lupus erythematosus (SLE).
AUTHOR: Davis John C Jr(a); Totoritis Mark C; Sklenar Thomas A; Wofsy David
AUTHOR ADDRESS: (a)San Francisco, CA**USA
JOURNAL: Arthritis & Rheumatism 42 (9 SUPPL.):pS281 Sept., 1999
CONFERENCE/MEETING: 63rd Annual Scientific Meeting of the American College of Rheumatology and the 34th Annual Scientific Meeting of the Association of Rheumatology Health Professionals Boston, Massachusetts, USA November 13-17, 1999
ISSN: 0004-3591
RECORD TYPE: Citation
LANGUAGE: English

Philip Gault
1644 6/23
09 874141

4/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

11995242 BIOSIS NO.: 199900275761
A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation.
AUTHOR: Chambers-Slater Karen(a); Brams Peter(a); Black Amelia(a); Padlan Eduardo A; Shestowsky William(a); Shearin Tracey(a); Nguyen Mai-Lan(a); Noelle Randolph J; Hanna Nabil(a); Newman Roland(a)
AUTHOR ADDRESS: (a)IDEC Pharmaceuticals Corporation, 11011 Torreyana Road, San Diego, CA, 92121**USA
JOURNAL: FASEB Journal 13 (5 PART 2):pA988 March 15, 1999
CONFERENCE/MEETING: Annual Meeting of the Professional Research Scientists on Experimental Biology 99 Washington, D.C., USA April 17-21, 1999
SPONSOR: Federation of American Societies for Experimental Biology
ISSN: 0892-6638
RECORD TYPE: Citation
LANGUAGE: English

4/3/9 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

12075716 EMBASE No: 2003187756
Sirolimus and islet transplants
Hering B.J.; Wijkstrom M.
Dr. B.J. Hering, Department of Surgery, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455 United States
Transplantation Proceedings (TRANSPLANT. PROC.) (United States) 2003 35/3 SUPPL. (187S-190S)
CODEN: TRPPA ISSN: 0041-1345
DOCUMENT TYPE: Journal ; Conference Paper
LANGUAGE: ENGLISH